Advancing Global Health

Gilead recognizes that the development of innovative medicines for life-threatening diseases is only one aspect of improving public health. We also invest in programs that promote prevention, strengthen healthcare infrastructure and provide education support and financial support to the most vulnerable communities around the world.

By enabling access to medicines, challenging assumptions, fighting stigma and collaborating with partners worldwide, we work not simply to treat some of the world’s most challenging public health threats – but to eliminate them.

Élargir l’accĂšs aux traitements dans les pays Ă  revenus faibles et intermĂ©diaires

Expanding Treatment Access in Low- and Middle-Income Countries

Gilead is committed to meeting with public health officials, doctors and patients around the world to understand barriers and opportunities in HIV, viral hepatitis and visceral leishmaniasis (VL).

Gilead and the WHO Tackle VL in Southeast Asia

Visceral leishmaniasis (VL) is a parasitic disease with an estimated 50,000 to 90,000 new cases worldwide each year, out of which only an estimated 25% to 45% are reported. VL is almost always fatal if untreated. We are collaborating with the World Health Organization (WHO) to provide treatments free of charge to all people diagnosed with the disease.

Gilead et l’OMS luttent contre la leishmaniose viscĂ©rale (LV) en Asie du Sud-Est

Gilead agit pour prĂ©venir l’infection par le VIH chez les adolescentes et les jeunes femmes dans 10 pays sub-sahariens.

Reducing HIV Infections Among Women in Sub-Saharan Countries

Gilead partners with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to help reduce HIV in adolescent girls and young women in 10 sub-Saharan African countries.